Paradiso A, Mangia A, Correale M, Abbate I, Ferri G, Piffanelli A, Catozzi L, Amadori D, Riccobon A, De Lena M
Experimental and Clinical Oncology Laboratory, Oncology Institute, Bari, Italy.
Breast Cancer Res Treat. 1992;23(1-2):63-70. doi: 10.1007/BF01831477.
Mitogenic properties have been demonstrated in vitro for the lysosomal acidic protease cathepsin-D (cath-D). We investigated possible relationships between cath-D cytosol cell content and tumor proliferative activity in a series of 129 operable breast cancer patients. For total cytosol cath-D evaluation, a solid phase two-site immunoradiometric assay was utilized on tumor cell cytosol obtained for hormone receptor assay (DCC method). The percentage of S-phase cells was analyzed by 3H-thymidine autoradiographic assay. Median 3H-thymidine Labeling Index (3H-Tdr-LI) of the series was 2.7%; median cath-D content resulted 57 pmol/mg of protein cytosol and was significantly higher in node-positive with respect to the node-negative subgroup (p < 0.03). When classified in low, intermediate or high tumor cath-D content and slow or fast proliferative activity (cut-off: median values of the series), no significant agreement was found between the two variables. Statistical analysis, however, showed that a significant inverse correlation existed in node positive tumors between cath-D and 3H-Tdr-LI values which was even more evident in N-positive high estrogen receptor-positive (ER+) cases (coefficient of correlation = 0.6828; p = 0.0001). Cytosol cath-D content cannot be generally proposed as a direct marker of proliferative activity for operable breast cancer.
溶酶体酸性蛋白酶组织蛋白酶-D(组织蛋白酶-D,cath-D)已在体外被证实具有促有丝分裂特性。我们对129例可手术乳腺癌患者进行了研究,以探讨组织蛋白酶-D胞浆细胞含量与肿瘤增殖活性之间的可能关系。为评估总胞浆组织蛋白酶-D,我们采用固相双位点免疫放射分析方法,对用于激素受体检测(DCC法)所获得的肿瘤细胞胞浆进行检测。通过3H-胸腺嘧啶放射自显影分析来检测S期细胞的百分比。该系列患者的3H-胸腺嘧啶标记指数(3H-Tdr-LI)中位数为2.7%;组织蛋白酶-D含量中位数为57 pmol/mg蛋白胞浆,且在淋巴结阳性亚组中显著高于淋巴结阴性亚组(p < 0.03)。当根据肿瘤组织蛋白酶-D含量低、中或高以及增殖活性慢或快进行分类时(分界点:该系列的中位数),未发现这两个变量之间存在显著一致性。然而,统计分析表明,在淋巴结阳性肿瘤中,组织蛋白酶-D与3H-Tdr-LI值之间存在显著负相关,在淋巴结阳性且雌激素受体阳性(ER+)的病例中更为明显(相关系数 = 0.6828;p = 0.0001)。对于可手术乳腺癌,一般不能将胞浆组织蛋白酶-D含量作为增殖活性的直接标志物。